Singapore, August 25, 2014 -- Moody's Investors Service says that India's pharmaceutical market will continue to grow in the double digits; a rate which is more favourable than most other markets for the industry. However, drug companies in the country could face higher debt levels, as the pharmaceutical sector in India grows, resulting in mergers and acquisitions.
Vollständigen Artikel bei Moodys lesen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.